Novo Nordisk Unveils New Hemophilia Data at ISTH Congress
Event summary
- Novo Nordisk will present new data on its hemophilia portfolio at the ISTH Congress 2026, including phase 3 FRONTIER4 study results for denecimig.
- Denecimig, an investigational bispecific antibody, is being evaluated across various dosing frequencies and age groups for hemophilia A patients.
- First-time data from the explorer10 study will assess concizumab's efficacy in pediatric hemophilia A or B patients with inhibitors.
- Novo Nordisk submitted denecimig for FDA review in September 2025 via a Biologics License Application (BLA).
The big picture
Novo Nordisk is expanding its presence in rare blood disorders, leveraging its diabetes care heritage to drive innovation. The ISTH Congress presentations underscore the company's commitment to addressing unmet needs in hemophilia treatment, particularly for pediatric patients and those with inhibitors. With denecimig's FDA submission already underway, the upcoming data could further solidify Novo Nordisk's strategic positioning in the hemophilia market.
What we're watching
- Regulatory Progress
- The pace at which denecimig advances through FDA review will determine its commercial viability.
- Clinical Efficacy
- Whether denecimig's flexible dosing regimen can demonstrate superior efficacy across different age groups and inhibitor statuses.
- Market Positioning
- How Novo Nordisk positions its hemophilia portfolio against competitors in a crowded therapeutic landscape.
Related topics